Matt Hougan

Matt Hougan is CEO of Inside ETFs, a division of Informa PLC. He spearheads the world's largest ETF conferences and webinars. Hougan is a three-time member of the Barron's ETF Roundtable and co-author of the CFA Institute’s monograph, "A Comprehensive Guide to Exchange-Trade Funds."

Features and News

S&P 500 Hits An All Time High… Really!

Owing to a runup of smaller stocks, and the woeful underperformance of some of the mega-caps, that other S&P 500 index, the equal-weighted version, has been on a run.

Features and News

An Index of Goodness

As innovative weighting schemes appear in the index business, there's now a new twist, an index weighted by "goodness"

Features and News

What You Don’t Know about the Consumer Price Index Could Hurt You

Taken for granted and critical for everything from cost of living increases to budgetary projections, the Consumer Price Index is a fluid and highly manipulated statistic.

Features and News

Scaling the Great Wall

With the NYSE launch of the FTSE Xinhua 25 China iShares fund, BGI has gone where no ETF provider has been able to go thusfar, into the future...into China

Journal Of Indexes

Coming Up Short?

A widely touted feature of ETFs is their shortability, but
investors are finding that many are difficult to short.

Features and News

The Incredible, Vanishing Index Effect: A Personal Reflection

A recent study from S&P highlighted the incrediby shrinking index effect. The author was there for it's heyday.

Features and News

Does the Index Fund Fee War Spell Trouble for ETFs?

Could the spate of lower index funds fees spell trouble for the boom in ETF assets?

Features and News

More Than Just a Pretty Picture

Backed by sophisticated new indexes and even investable products, some investors see art assuming the mantel as an alternative asset class.

Features and News

Why Stock Selection Matters … Even for Index Investors

Sometimes indexes purporting to cover the same asset class can have vastly different underlying constituents, volatility and performance - take biotech, for example